Japanese Healthtech Stock News

TSE:8306
TSE:8306Banks

Mitsubishi UFJ Financial Group (TSE:8306) Valuation Check After Reaffirmed Profit And Dividend Targets

Mitsubishi UFJ Financial Group (TSE:8306) has drawn fresh attention after an interim audit review left its nine month Japanese GAAP results unchanged, while management reaffirmed a ¥2.1t full year profit target and a ¥74 per share dividend. See our latest analysis for Mitsubishi UFJ Financial Group. The earnings confirmation and guidance reiteration come after a strong run in the shares, with the 90 day share price return of 22.52% and a 1 year total shareholder return of 59.67% pointing to...
TSE:8113
TSE:8113Household Products

What Unicharm (TSE:8113)'s Buyback After Guidance Cut Means For Shareholders

On February 12, 2026, Unicharm Corporation’s board approved a share repurchase program of up to 30,000,000 shares, or 1.72% of its capital, for ¥19,000 million running through December 17, 2026, following a prior downward revision of its 2025 earnings guidance due to weaker performance in China and Indonesia and impairment charges in Asia and India. This sequence of a profit warning and a sizeable buyback authorization highlights management’s focus on shareholder returns while addressing...
TSE:3088
TSE:3088Consumer Retailing

How Leadership Overhaul and 2026 Earnings Guidance Will Impact MatsukiyoCocokara (TSE:3088) Investors

MatsukiyoCocokara recently issued earnings guidance for the year ending March 31, 2026, forecasting net sales of ¥1.10 trillion, operating profit of ¥85.50 billion, profit attributable to owners of parent of ¥56.50 billion and basic earnings per share of ¥141.67, alongside board-approved changes to representative directors and other senior roles effective April 1, 2026. By pairing a comprehensive leadership reshuffle with quantified profit and dividend confidence, the company is signaling an...
TSE:2587
TSE:2587Beverage

Suntory Beverage And Food TSE 2587 Net Margin Slippage Tests Bullish Valuation Narrative

Latest FY 2025 Results Set the Stage for Suntory Beverage & Food Suntory Beverage & Food (TSE:2587) has just released its FY 2025 numbers, with fourth quarter revenue of ¥437.4 billion and basic EPS of ¥43.23, alongside trailing twelve month EPS of ¥287.13 on revenue of ¥1.72 trillion. Over recent periods, revenue has moved from ¥419.1 billion and EPS of ¥33.12 in Q4 2024 to ¥471.7 billion and EPS of ¥110.77 in Q3 2025, before settling at the latest Q4 levels. This gives investors a fresh...
TSE:5711
TSE:5711Metals and Mining

Mitsubishi Materials (TSE:5711) Q3 EPS Surge Tests High P/E Bullish Narratives

Mitsubishi Materials (TSE:5711) Q3 2026 earnings snapshot Mitsubishi Materials (TSE:5711) has reported Q3 2026 revenue of ¥454.6b and basic EPS of ¥236.47, backed by net income of ¥30.9b for the quarter. The company’s revenue moved from ¥494.1b in Q3 2025 to ¥454.6b in Q3 2026, while quarterly EPS shifted from ¥187.54 to ¥236.47 over the same period, against a trailing twelve month EPS of ¥162.93 on revenue of ¥1.76t. This combination of a softer top line and firmer per share earnings focuses...
TSE:1605
TSE:1605Oil and Gas

Inpex (TSE:1605) Margin Resilience Challenges Bearish Earnings Decline Narrative

Inpex (TSE:1605) has just wrapped up FY 2025 with fourth quarter revenue of ¥490,704 million and basic EPS of ¥86.17, while trailing twelve month figures sit at ¥2.0 trillion in revenue and EPS of ¥337.94, giving investors a clear view of both the latest quarter and the full year run rate. Over recent periods, revenue has moved from ¥518,280 million and EPS of ¥115.17 in Q4 2024 to ¥490,704 million and EPS of ¥86.17 in Q4 2025, with trailing net profit margin at 19.6% compared with 18.9% a...
TSE:4506
TSE:4506Pharmaceuticals

Assessing Sumitomo Pharma (TSE:4506) Valuation As AMCHEPRY Faces Key Parkinson’s Disease Review

Sumitomo Pharma (TSE:4506) is back on investors’ radar after Japan’s Ministry of Health, Labour and Welfare scheduled a February 19 committee review of AMCHEPRY, its allogeneic iPS cell derived therapy for advanced Parkinson’s disease. See our latest analysis for Sumitomo Pharma. The upcoming AMCHEPRY review arrives after a volatile few months, with a 10.81% 7 day share price return and a 14.19% 30 day share price decline. At the same time, a very large 1 year total shareholder return of...